United Therapeutics (UTHR) has provided an announcement.
At the 2024 Annual Meeting of Shareholders, all director nominees were elected with a clear majority, with Jan Malcolm receiving the highest support. Shareholders also approved executive compensation, the restatement of the stock incentive plan, and the appointment of Ernst & Young as the public accounting firm. This demonstrates strong shareholder confidence in the company’s governance and strategic financial decisions.
See more data about UTHR stock on TipRanks’ Stock Analysis page.
